Zevalin
Sponsors
Dana-Farber Cancer Institute, M.D. Anderson Cancer Center, Spectrum Pharmaceuticals, Inc, A.O. Ospedale Papa Giovanni XXIII, Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
Conditions
CD20+ Aggressive Non-Hodgkin's LymphomaDiffuse Large B-Cell LymphomaDiffuse Large B-cell LymphomaDiffuse Large Cell LymphomaFollicle Center LymphomaFollicular LymphomaLymphomaLymphoma, Large Cell, Diffuse
Phase 2
Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma
CompletedNCT00119730
Start: 2005-02-28End: 2013-12-31Updated: 2014-04-24
Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma
CompletedNCT00290511
Start: 2004-06-29End: 2021-02-12Updated: 2022-04-22
Fludarabine,Cyclophosphamide and Rituximab Followed by Zevalin for Non-Follicular Indolent Lymphomas.
TerminatedNCT00354822
Start: 2005-08-31End: 2009-08-31Updated: 2009-09-18
Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas
TerminatedNCT00493454
Start: 2006-04-30End: 2011-03-31Updated: 2013-05-31
A Study of Zevalin and Simultaneous Application of BEAM High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Refractory and Relapsed Aggressive Non-Hodgkin Lymphomas
CompletedNCT00521560
Start: 2006-03-31End: 2012-08-31Updated: 2013-02-15
Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation
CompletedNCT00591630
Start: 2007-11-14End: 2020-03-05Updated: 2021-02-02
Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) in Elderly (More Than 60 Years) Patients With Diffuse Large B Cell Lymphoma After 4 Cycles of CHOP21-Rituximab (CHOP21-R) Therapy
CompletedNCT00850512
Updated: 2009-02-25
Phase 3
Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.
TerminatedNCT00322218
Start: 2006-05-31End: 2008-12-31Updated: 2022-01-19
Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy
TerminatedNCT01510184
Start: 2012-04-19End: 2014-10-23Updated: 2021-12-16
Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)
TerminatedNCT01662102
Start: 2012-12-11End: 2013-03-05Updated: 2021-10-04
A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)
CompletedNCT01827605
Start: 2012-01-01End: 2024-01-01Updated: 2026-09-09